Cardiac Cell Therapy and Bypass Surgery

Author(s): Yeong-Hoon Choi, Boris Nasseri, Christof Stamm

Journal Name: Current Pharmaceutical Design

Volume 17 , Issue 30 , 2011

Become EABM
Become Reviewer
Call for Editor


More than 10 years ago, the first clinical application of cardiac cell therapy was performed in a patient undergoing coronary bypass grafting (CABG). Ever since, catheter-based cell delivery approaches have dominated the field, but surgical cell therapy continues to provide important information on safety and efficacy of various cell therapy strategies. The open chest offers unrivalled simplicity and precision of intramyocardial cell injection, and the cardiac surgical patient population includes those with very advanced heart disease who are in greatest need of innovative regeneration concepts. In this review, the clinical experience with cardiac surgical cell therapy is summarized and critically appraised.

Keywords: Stem cell, surgery, heart, myocardial infarction, heparinization, myocardium, bone marrow, transplantation, cardiac cell therapy, angiogenesis

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2011
Published on: 01 March, 2012
Page: [3348 - 3355]
Pages: 8
DOI: 10.2174/138161211797904145
Price: $65

Article Metrics

PDF: 3